Stocks · News reference
After Braze, Could Klaviyo Be Big Tech’s Next Billion-Dollar Bet?
Salesforce’s $5.66 billion Braze deal puts Klaviyo in focus as investors weigh the value of customer-engagement software.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Downgrades Braze to Perform
Oppenheimer analyst Brian Schwartz downgrades Braze (NASDAQ:BRZE) from Outperform to Perform.
Stifel Downgrades Braze to Hold, Raises Price Target to $47.5
Stifel analyst Parker Lane downgrades Braze (NASDAQ:BRZE) from Buy to Hold and raises the price target from $35 to $47.5.
CrowdStrike vs. Docusign: Which Technology Stock Is a Better Buy in 2026?
CrowdStrike and Docusign represent two distinct paths in software: CrowdStrike leads in AI-native cybersecurity with 21.7% revenue growth but trades at a 192.6x forward P/E, while Docusign offers profitable operations with 8.2% growth and a 16.7x forward P/E. The author recommends CrowdStrike for stronger long-term growth potential despite higher valuation and volatility from its 2024 outage recovery.
Why Is Braze Stock Surging on Tuesday?
Braze shares surged after Salesforce announced an acquisition offering a roughly 58% premium to the stock’s Friday closing price of $30.04.
Health Care Stocks Hit Record Highs, GM Drops Nearly 8%: Stock Market Today
Health care stocks climbed to record highs by midday Tuesday, with defensives and small caps leading a recovery from an early dip.